The new Bilbao center adds mRNA drug substance, lipid nanoparticle formulation, and GMP drug product manufacturing capabilities to the company’s genetic medicines operations.
The expanded agreement gives viral vector developers access to research-use and GMP-grade synthetic DNA for cell and gene therapy development programs.
Learn how oxygen-enriched biological treatment helps pharmaceutical manufacturers unlock up to 50% additional wastewater treatment capacity, improve oxygen transfer efficiency, and maximize the performance of existing wastewater treatment assets.
